OMBCL Shorts #2: Dr. Erika Hamilton with Top Takeaways from ASCO23
This is our second episode of the Summer 23 season. You might recall that a few months ago we introduced you to the new series under the new brand #OMBCLShorts. As the title implies, these are shorter episodes. Some will be the outtakes of the amazing interviews that we had done, others brand new shorter interviews. We have so many incredible guests and we want to make sure that you hear what they have to say.
Unlike the irst short that featured Dr. Stephanie Graff in an outtake from an interview that Lynda Weatherby and Victoria Goldberg produced earlier in the season, this short feature with Dr. Erika Hamilton is a brand new interview.
A couple of weeks after the 2023 Annual Conference of the American Society of Clinical Oncologists (ASCO), Victoria Goldberg met with Dr. Hamilton to get her take on what were the biggest developments in MBC at ASCO this year. To our surprise, Dr. Hamilton thought that the abstract that had stolen the show were the primary results of the Phase 3 NATALEE study (NCT03701334) presented at ASCO by Dr. Dennis Salmon.
Monarch E, a similar early stage trial that tested abemacyclib was presented by Dr. Hamilton at the same conference. Obviously these are early stage trials and their results do not affect us directly, but any positive trial of a drug that is a standard of care for most MBC patients will affect us indirectly and is always worth mentioning. We discuss these trials, the new findings on capecitabine, and finally a novel HER3-targeted ADC that shows promise. The results of a phase II clinical trial were presented by Dr. Hamilton on June 5th at the 2023 ASCO conference and they support the use of patritumab deruxtecan as a treatment option for HER2-negative metastatic breast cancer,
On June 12th 2023 just a few days before this conversation. Astro Zeneca issued a press release that announced that based on CAPItello-291 Phase III trial results the FDA accepted and granted priority review to their first-in-class AKT inhibitor capivasertib.
Meet the Guest of the Episode
Erika P. Hamilton, MD
Director, Breast Cancer and Gynecologic Cancer Research, Sarah Cannon Research Institute(SCRI)
She oversees the program and the clinical trial menu for these cancers across the SCRI network.
Dr. Hamilton joined SCRI in 2013 as an investigator in drug development for women’s cancers, and has served as director of breast cancer and gynecologic cancer research since 2015. Her mother is a BC survivor, who was diagnosed with breast cancer when Dr. Hamilton was in middle school. Dr. Hamilton is passionate about personalized treatment, empowering her patients, and treating each person individually based on their goals and preferences.
Dr. Hamilton received her undergraduate degree from Washington and Lee University in Virginia and received a NCAA Postgraduate Scholarship. She then completed her medical degree and residency from University of North Carolina in Chapel Hill and fellowship training in hematology and oncology at Duke University, where she was recognized as a Top 5 Finalist for Duke's Annual House staff Fellow Teaching Award.
Dr. Hamilton was named to the Women to Watch Class of 2021 for Nashville Medical News. She was selected for the American Society of Clinical Oncology’s (ASCO) Leadership Development Class for 2021-2022, and was the past chair of ASCO’s Scientific Committee for Metastatic Breast Cancer for 2019-2020. She is the 2023-2025 Scientific Committee co-chair of the ESMO Breast Cancer Meeting, serves on ASCO’s Cancer Research Committee, ASCO’s Digital Content Committee, and is an associate editor for Clinical Breast Cancer.
